08

November

2022

|

07:thirty AM

Europe/Amsterdam

3rd quarter of 2022

Summary

Group income maximize by 5.7 % (Fx & portfolio adj.) to eleven.281 billion euros  / EBITDA before exclusive objects rises by 17.three percent to 2.451 billion euros / Crop Science achieves strong gross sales gains – sales also up at Pharmaceuticals and Purchaser Overall health / All divisions report important raise in earnings / Core earnings for each share climb by seven.6 percent to one.13 euros / Internet earnings at 546 million euros / Cost-free cash movement at 1.738 billion euros / Important progress in Pharmaceuticals pipeline / Entire-calendar year Team outlook confirmed